Program
Linagliptin
Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.
Drug pageLinagliptin: every studyMany companies study it; this page follows only the 89 they lead. All 129 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 800 open or running | phase 4since Sep 21, 2011 | Mar 31, 2006 | none ahead |
| Dong Wha Pharmaceuticalits history only | 30 open or running | phase 1since Aug 6, 2014 | Aug 6, 2014 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 4since Jul 11, 2013 | Jul 11, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 3, 2016 | Aug 3, 2016 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 3since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Marcus Borchertits history only | 10 open or running | phase 4since Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: Halozyme Therapeutics, BioLineRx, Eli Lilly, Eva Pharma, Ikfe and MLM Medical Labs.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Sep 21, 2011.
- Aug 19, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02221414, NCT02221401, NCT02220647
- Sep 15, 2014Phase 4 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02240680 · 302 enrolled · United States, Australia, Belgium and more
- Dec 11, 2014Phase 4 study in Diabetes Mellitus, Type 2Profil Institut für Stoffwechselforschung · NCT02401880 · 89 enrolled · Germany
- Feb 11, 2015ikfe-CRO’s first study: phase 3 study in HypertensionNew to ikfe-CROikfe-CRO · NCT02376075 · 43 enrolled · Germany
- May 21, 2015Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02453555 · 275 enrolled · Japan
- Apr 29, 2016Phase 1 study in HealthyBoehringer Ingelheim · NCT02758171 · 56 enrolled · Germany
- Jun 24, 20162 phase 1 studies in HealthyBoehringer Ingelheim · NCT02815644, NCT02821910
- Aug 3, 2016Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02857946 · 24 enrolled · Egypt
- Aug 30, 2016Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02897349 · 206 enrolled · China
- Aug 22, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03259490 · 30 enrolled · Germany
- Feb 6, 2018Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT03429543 · 175 enrolled · United States, Argentina, Brazil and more
- Aug 9, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03629054 · 30 enrolled · Germany
- Apr 6, 20232 phase 1 studies in Healthy SubjectsDong Wha Pharmaceutical · NCT05874180, NCT05874167
- Feb 19, 2025Nabiqasim Industries (Pvt)’s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
TargetBeta
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 89 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Apr 30, 2026 | 800 |
| NCT05874180Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Feb 1, 2023 | 31 |
| NCT05874167Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Oct 11, 2022 | 50 |
| NCT03629054Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 5, 2018 | 30 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Boehringer Ingelheim | Oct 19, 2022 | 175 |
| NCT03259490Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 13, 2017 | 30 |
| NCT02897349Diabetes Mellitus, Type 2 · China | 3 | Completed | Boehringer Ingelheim | Jan 11, 2019 | 206 |
| NCT02857946Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2016 | 24 |
| NCT02821910Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 5, 2016 | 22 |
| NCT02758171Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 29, 2016 | 56 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Aug 26, 2016 | 275 |
| NCT02376075Hypertension · Germany | 3 | Completed | ikfe-CRO | Sep 2014 | 43 |
| NCT02401880Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Dec 2015 | 89 |
| NCT02240680Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 4 | Completed | Boehringer Ingelheim | Apr 18, 2017 | 302 |
| NCT02221414Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2010 | 95 |
| NCT02221401Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2010 | 96 |
| NCT02220647Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2010 | 96 |
| NCT02212782Healthy · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Nov 2014 | 12 |
| NCT02191228Renal Insufficiency | 1 | Completed | Boehringer Ingelheim | Feb 2010 | 51 |
| NCT02183636Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2009 | 39 |
| NCT02183623Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 20 |
| NCT02183610Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2006 | 12 |
| NCT02183584Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2009 | 16 |
| NCT02183532Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 12 |
| NCT02183506Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2005 | 16 |
| NCT02183493Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 32 |
| NCT02183480Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2009 | 12 |
| NCT02183467Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2008 | 44 |
| NCT02183428Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2008 | 20 |
| NCT02183415Diabetes Mellitus, Type 2 | 1 | Completed | Boehringer Ingelheim | Jan 2006 | 77 |
| NCT02183402Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2008 | 20 |
| NCT02183389Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 18 |
| NCT02183376Hepatic Insufficiency | 1 | Completed | Boehringer Ingelheim | Mar 2009 | 33 |
| NCT02183363Healthy | 1 | Completed | Boehringer Ingelheim | May 2007 | 24 |
| NCT02183350Diabetes Mellitus, Type 2 | 1 | Completed | Boehringer Ingelheim | Aug 2005 | 47 |
| NCT02183337Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2007 | 20 |
| NCT02183324Diabetes Mellitus, Type 2 | 2 | Completed | Boehringer Ingelheim | Jun 2007 | 72 |
| NCT02183311Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2006 | 56 |
| NCT02183298Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 36 |
| NCT02180503Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 24 |
| NCT02175394Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 18 |
| NCT02173665Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2004 | 64 |
| NCT02173652Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2008 | 16 |
| NCT02173639Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2009 | 20 |
| NCT02121509Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 74 |
| NCT02084082Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 68 |
| NCT02084056Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 74 |
| NCT01947153Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Jan 2014 | 36 |
| NCT01903070Diabetes Mellitus · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Apr 2016 | 99 |
| NCT01897532Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 4 | Completed | Boehringer Ingelheim | Jan 18, 2018 | 6,991 |
| NCT01845077Healthy · United States | 1 | Completed | Boehringer Ingelheim | Aug 2013 | 72 |
| NCT01792518Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Boehringer Ingelheim | Nov 2015 | 360 |
| NCT01708902Diabetes Mellitus, Type 2 · China, Malaysia, Philippines and more | 3 | Completed | Boehringer Ingelheim | Apr 2014 | 876 |
| NCT01703286Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Boehringer Ingelheim | Jan 2014 | 42 |
| NCT01581931Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2012 | 32 |
| NCT01540487Healthy · China | 1 | Completed | Boehringer Ingelheim | Jun 2012 | 48 |
| NCT01547104Diabetes Mellitus, Type 2 · Germany | 4 | UNKNOWN | Marcus Borchert | Oct 2012 | 40 |
| NCT01512979Diabetes Mellitus, Type 2 · United States, Canada, India and more | 4 | Completed | Boehringer Ingelheim | Apr 2013 | 316 |
| NCT01438814Diabetes Mellitus, Type 2 · Bangladesh, Belgium, Canada and more | 4 | Completed | Boehringer Ingelheim | Mar 2013 | 689 |
How it is read
Names in the registry
- “Linagliptin”, 35 entries
- “BI 1356”, 14 entries
- “linagliptin”, 10 entries
- “Linagliptin/Metformin FDC”, 4 entries
- “BI 1356 BS”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 46 studies
- Diabetes Mellitus, 2 studies
- Esophageal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.